Overview

Proactive Care of Ambulatory COVID19 Patients

Status:
Not yet recruiting
Trial end date:
2020-07-01
Target enrollment:
0
Participant gender:
All
Summary
On January 9, 2020, a new emerging virus was identified by WHO as being responsible for grouped cases of pneumonia in China. It is a coronavirus, SARS-CoV-2, responsible for the disease COVID-19 (Coronavirus disease). The disease is mild in 85% of cases but the proportion of serious cases requiring hospitalization or intensive care (15%) puts stress on health structures and systems around the world. To limit the influx of patients and avoid overstretching Health systems, containment and social distancing strategies are widely adopted. It appears crucial to propose the easiest possible therapeutic strategy taking into account the ambulatory nature of the patients. Therefore azithromycin (AZM) is an antibiotic known to have an antiviral effect but also which has anti-inflammatory activity in addition to its antimicrobial effect. Azithromycin targets preferentially pulmonary cells (and particularly of the lines apparently affected in COVID-19 positive cases). The aim of this study is to demonstrate that AZM decreases symptom duration in COVID19 patients and diminishes the viral carriage.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Treatments:
Azithromycin
Criteria
Inclusion Criteria:

- Patients treated at the CHU Amiens Picardie presenting:

- Age ≥18 years

- Showing symptoms of COVID -19 and a positive RT-PCR by nasopharyngeal swab

- Non-severe patient, outpatient (not hospitalized), without oxygen

- Having signed a consent to participate in the study

Exclusion Criteria:

- Patient with a contraindication to taking azithromycin, namely: Allergy to macrolides,
Severe liver failure.

- In combination with medicines containing cisapride, colchicine, ergotamine or
dihydroergotamine

- Pregnant, parturient or breastfeeding women.

- Asymptomatic patients

- Patient unable to be compliant with study protocol

- Patient under guardianship or curators, under the protection of justice or private
public law.